Complete enrollment in the Phase 3 study of mRNA-1273
Delivered after the deadline (22 days after the deadline)
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 5 Aug 2020
- Due
- 30 Sep 2020
- Delivered
- 22 Oct 2020
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Phase 3 study of mRNA-1273 being conducted in collaboration with NIH and BARDA on track to complete enrollment in September 2020”
What we found
Evidence strength A What the grades mean
Enrollment in the Phase 3 COVE study completed on October 22, 2020, about three weeks after the September 2020 deadline; enrollment had been slowed in early September.
-
A Moderna 8-K filed 2020-10-29
“On October 22, the Phase 3 COVE study of COVID vaccine candidate (mRNA-1273) being conducted with NIH and BARDA completed enrollment” ✓ confirmed on the page
-
A Moderna 10-K filed 2021-02-26
“completed enrollment of more than 30,000 participants ages 18 and older in the U.S. on October 22, 2020” ✓ confirmed on the page
-
A Moderna 10-K filed 2021-02-26
“In early September 2020, we announced that we were slowing enrollment in the trial to ensure representation of communities of color in the COVE study.” ✓ confirmed on the page
Market reaction: the shares moved +1.0% against the S&P 500 over the three sessions around the disclosure (28 Oct 2020 to 2 Nov 2020). What this measures
Checked 10 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Complete
- Deliverable
- Phase 3 enrollment for mRNA-1273 COVID-19 vaccine study
- Language
- Firm (“will”, “on track to”)
- In the company’s control
- Medium
- Specificity
- Medium
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Moderna? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2020-MRNA-006145 · Corrections policy